KR20090024748A - 인간화 항인간 오스테오폰틴 항체 - Google Patents

인간화 항인간 오스테오폰틴 항체 Download PDF

Info

Publication number
KR20090024748A
KR20090024748A KR1020087031918A KR20087031918A KR20090024748A KR 20090024748 A KR20090024748 A KR 20090024748A KR 1020087031918 A KR1020087031918 A KR 1020087031918A KR 20087031918 A KR20087031918 A KR 20087031918A KR 20090024748 A KR20090024748 A KR 20090024748A
Authority
KR
South Korea
Prior art keywords
ser
val
antibody
thr
gly
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020087031918A
Other languages
English (en)
Korean (ko)
Inventor
노부치카 야마모토
후미히코 사카이
히로후미 히구치
마사하루 토리카이
토시히로 나카시마
Original Assignee
아스텔라스세이야쿠 가부시키가이샤
자이단호진 가가쿠오요비겟세이료호겐쿠쇼
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 아스텔라스세이야쿠 가부시키가이샤, 자이단호진 가가쿠오요비겟세이료호겐쿠쇼 filed Critical 아스텔라스세이야쿠 가부시키가이샤
Publication of KR20090024748A publication Critical patent/KR20090024748A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physics & Mathematics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
KR1020087031918A 2006-05-31 2007-05-30 인간화 항인간 오스테오폰틴 항체 Ceased KR20090024748A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006152892 2006-05-31
JPJP-P-2006-152892 2006-05-31

Publications (1)

Publication Number Publication Date
KR20090024748A true KR20090024748A (ko) 2009-03-09

Family

ID=38778682

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020087031918A Ceased KR20090024748A (ko) 2006-05-31 2007-05-30 인간화 항인간 오스테오폰틴 항체

Country Status (17)

Country Link
US (1) US7807161B2 (de)
EP (1) EP2025749B8 (de)
JP (1) JP4064441B2 (de)
KR (1) KR20090024748A (de)
CN (1) CN101495632B (de)
AT (1) ATE553130T1 (de)
AU (1) AU2007268591A1 (de)
BR (1) BRPI0711229A2 (de)
CA (1) CA2653661A1 (de)
ES (1) ES2384350T3 (de)
IL (1) IL195503A0 (de)
MX (1) MX2008015309A (de)
NO (1) NO20085282L (de)
RU (1) RU2429016C2 (de)
TW (1) TW200813087A (de)
WO (1) WO2007139164A1 (de)
ZA (1) ZA200810863B (de)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2711882C (en) 2008-01-11 2016-07-19 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute Improved humanized anti-human .alpha.9-integrin antibody
JP5339748B2 (ja) * 2008-03-11 2013-11-13 国立大学法人北海道大学 ヒトオステオポンチンの活性化を阻害する物質をスクリーニングする方法
CN102027013B (zh) * 2008-04-24 2015-01-14 株式会社遗传科技 细胞外基质蛋白的氨基酸序列rgd的特异性人源化抗体及其应用
JP5765814B6 (ja) 2009-10-21 2018-06-27 国立大学法人広島大学 インテグリンα８β１特異的モノクローナル抗体
WO2012050646A2 (en) 2010-06-29 2012-04-19 The Trustees Of The University Of Pennsylvania Biomimetic chemical sensors using nanoelectronic readout of olfactory receptors
WO2013033359A1 (en) * 2011-08-31 2013-03-07 The Trustees Of The University Of Pennsylvania Carbon nanotube biosensors and related methods
WO2014061783A1 (ja) 2012-10-19 2014-04-24 株式会社イーベック クロストリジウム・ディフィシルの毒素に特異的なヒト抗体もしくはその抗原結合性断片
US9649375B2 (en) 2013-03-14 2017-05-16 The Administrators Of The Tulane Educational Fund Immunogenic peptide conjugate and method for inducing an anti-influenza therapeutic antibody response therewith
CN104250302B (zh) 2013-06-26 2017-11-14 上海君实生物医药科技股份有限公司 抗pd‑1抗体及其应用
TW201623329A (zh) * 2014-06-30 2016-07-01 亞佛瑞司股份有限公司 針對骨調素截斷變異體的疫苗及單株抗體暨其用途
US11415546B2 (en) 2014-09-05 2022-08-16 The Trustees Of The University Of Pennsylvania Volatile organic compound-based diagnostic systems and methods
EP3482096B1 (de) 2016-07-06 2023-02-22 Dana Automotive Systems Group, LLC Verbindungsanordnung zur schnellkupplung von achse und propellerwelle
KR20180000875U (ko) 2016-09-21 2018-03-29 전은희 조명 모듈
WO2018119142A1 (en) 2016-12-21 2018-06-28 Amgen Inc. Anti-tnf alpha antibody formulations
CN112480250B (zh) * 2020-12-23 2022-03-15 上海交通大学 一种抗人骨桥蛋白的抗体及其应用
US20230272058A1 (en) * 2021-07-02 2023-08-31 Washington University Compositions and methods for preventing acute kidney injury-induced acute lung injury (aki-ali)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL162181A (en) 1988-12-28 2006-04-10 Pdl Biopharma Inc A method of producing humanized immunoglubulin, and polynucleotides encoding the same
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994020632A1 (fr) 1993-03-11 1994-09-15 Juridical Foundation The Chemo-Sero-Therapeutic R Esearch Insitute Anticorps monoclonal dirige contre le vih
DE4425115A1 (de) 1994-07-15 1996-01-18 Boehringer Mannheim Gmbh Verfahren zur Modifizierung der Stabilität von Antikörpern
CA2267620A1 (en) * 1996-07-16 1998-01-22 Andreas Pluckthun Immunoglobulin superfamily domains and fragments with increased solubility
US20040234524A1 (en) 2001-04-05 2004-11-25 Toshimitsu Uede Anti-osteopontin antibody and use thereof
CA2453662A1 (en) * 2001-07-19 2003-01-30 Stefan Ewert Modification of human variable domains
JPWO2003027151A1 (ja) * 2001-09-25 2005-01-06 株式会社 免疫生物研究所 組換え抗オステオポンチン抗体およびその用途
WO2006043954A1 (en) 2004-10-13 2006-04-27 Genentech, Inc. Method for treating tumors using anti-osteopontin antibodies
US7456260B2 (en) * 2002-06-17 2008-11-25 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Humanized antibody
EP1637159A4 (de) 2003-05-23 2009-01-21 Immuno Biological Lab Co Ltd Immunkompetenter zellaktivierungshemmer und seine verwendung
JP2006152892A (ja) 2004-11-29 2006-06-15 Anest Iwata Corp 気体吸排機械
CA2596925C (en) * 2005-02-08 2017-07-04 Km Biologics Co., Ltd. Method for improving expression level and stability of antibody

Also Published As

Publication number Publication date
EP2025749A1 (de) 2009-02-18
RU2429016C2 (ru) 2011-09-20
EP2025749B1 (de) 2012-04-11
US7807161B2 (en) 2010-10-05
ES2384350T3 (es) 2012-07-04
JP4064441B2 (ja) 2008-03-19
AU2007268591A1 (en) 2007-12-06
RU2008152769A (ru) 2010-07-20
IL195503A0 (en) 2011-08-01
EP2025749A4 (de) 2009-12-16
CN101495632B (zh) 2011-08-03
EP2025749B8 (de) 2012-05-23
CN101495632A (zh) 2009-07-29
WO2007139164A1 (ja) 2007-12-06
ZA200810863B (en) 2010-08-25
BRPI0711229A2 (pt) 2013-01-08
NO20085282L (no) 2009-02-26
MX2008015309A (es) 2009-03-02
TW200813087A (en) 2008-03-16
ATE553130T1 (de) 2012-04-15
CA2653661A1 (en) 2007-12-06
JP2008005836A (ja) 2008-01-17
US20090053212A1 (en) 2009-02-26

Similar Documents

Publication Publication Date Title
KR20090024748A (ko) 인간화 항인간 오스테오폰틴 항체
JP6827583B2 (ja) Ｄｌｌ３及びｃｄ３に結合する二重特異性抗体構築物
JP7325936B2 (ja) 改善された貯蔵及び投与のための、二重特異性抗体構築物を含む医薬組成物
KR102688969B1 (ko) Bcma 및 cd3 이중특이성 t 세포 맞물림 항체 작제물
KR102914586B1 (ko) 메소텔린 및 cd3에 결합하는 이중특이적 항체 작제물
JP2019048896A (ja) ヒトタンパク質チロシンホスファターゼβ（ＨＰＴＰβ）に結合する抗体及びその使用
KR20260028110A (ko) 이중특이성 t 세포 맞물림 항체 작제물
KR20120024952A (ko) 뇌 질환의 치료를 위한 항-타우 ｐｓ422 항체의 용도
JP2023134497A (ja) Ｍｕｃ１７及びｃｄ３に向けられる二重特異性抗体コンストラクト
CN105121468A (zh) 用于cdh19和cd3的抗体构建体
KR20170029508A (ko) 신규 항인간 Tie2 항체
CN116731169A (zh) 一种分拣蛋白1特异性的纳米抗体及其应用
WO2022194201A1 (zh) 一种靶向cldn18.2的抗体或其抗原结合片段及其应用
RU2503720C2 (ru) УЛУЧШЕННОЕ ГУМАНИЗИРОВАННОЕ АНТИТЕЛО К ЧЕЛОВЕЧЕСКОМУ α9-ИНТЕГРИНУ
CN110885377B (zh) 抗cd47/vegf双特异性抗体及其应用
TW201102086A (en) Antibodies against human CCN1 and uses thereof
JP6925274B2 (ja) 治療
JP2026500703A (ja) 融合タンパク質
CN110734494A (zh) 抗tspan8单克隆抗体及其用途
WO2024059675A2 (en) Bispecific molecule stabilizing composition
CA2502668C (en) Fully human antibody fab fragments with human interferon-gamma neutralizing activity
HK40118737A (zh) 结合vegf和tie2的融合蛋白及其用途
BR112020013018B1 (pt) Construto de anticorpo biespecífico, seu uso e composição farmacêutica

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20081230

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20120518

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20140127

Patent event code: PE09021S01D

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20140416

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20140127

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I